Capmatinib‑associated interstitial lung disease in a patient with lung adenocarcinoma harboring a skipping mutation of mesenchymal‑epithelial transition exon 14: A case report

Capmatinib is a medication used to treat patients with non-small cell lung cancer (NSCLC) who have a specific genetic mutation known as a mesenchymal-epithelial transition exon 14 skipping mutation. Previous clinical trials have reported that capmatinib treatment has a high objective response rate i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Bing-Jie, Chang, Cheng-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502934/
https://www.ncbi.nlm.nih.gov/pubmed/37720677
http://dx.doi.org/10.3892/ol.2023.14042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502934/
https://www.ncbi.nlm.nih.gov/pubmed/37720677
http://dx.doi.org/10.3892/ol.2023.14042

Ejemplares similares